Log in

NASDAQ:XERS - Xeris Pharmaceuticals Stock Price, Forecast & News

$4.00
-0.13 (-3.15 %)
(As of 02/17/2020 01:22 AM ET)
Add
Today's Range
$3.87
Now: $4.00
$4.19
50-Day Range
$4.00
MA: $6.09
$7.45
52-Week Range
$3.84
Now: $4.00
$12.98
Volume766,021 shs
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Xeris Pharmaceuticals, Inc, a specialty pharmaceutical company, develops and commercializes ready-to-use injectable and infusible drug formulations. Its proprietary XeriSol and XeriJect formulation technologies allow for the subcutaneous and intramuscular delivery of highly-concentrated, ready-to-use formulations of peptides, proteins, antibodies, and small molecules using commercially available syringes, auto-injectors, multi-dose pens, and infusion pumps. Read More…

Industry, Sector and Symbol

Industry N/A
Sub-IndustryN/A
SectorN/A
Current SymbolNASDAQ:XERS
CUSIPN/A
CIKN/A
WebN/A
PhoneN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Employees90
Next Earnings Date3/4/2020 (Estimated)
OptionableNot Optionable

Receive XERS News and Ratings via Email

Sign-up to receive the latest news and ratings for XERS and its competitors with MarketBeat's FREE daily newsletter.


Xeris Pharmaceuticals (NASDAQ:XERS) Frequently Asked Questions

What is Xeris Pharmaceuticals' stock symbol?

Xeris Pharmaceuticals trades on the NASDAQ under the ticker symbol "XERS."

How were Xeris Pharmaceuticals' earnings last quarter?

Xeris Pharmaceuticals Inc (NASDAQ:XERS) released its earnings results on Thursday, November, 7th. The company reported ($1.22) EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($1.23) by $0.01. The business had revenue of $0.32 million for the quarter, compared to analysts' expectations of $0.20 million. View Xeris Pharmaceuticals' Earnings History.

When is Xeris Pharmaceuticals' next earnings date?

Xeris Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Wednesday, March 4th 2020. View Earnings Estimates for Xeris Pharmaceuticals.

What price target have analysts set for XERS?

2 brokerages have issued twelve-month target prices for Xeris Pharmaceuticals' stock. Their forecasts range from $18.00 to $22.00. On average, they expect Xeris Pharmaceuticals' stock price to reach $20.00 in the next twelve months. This suggests a possible upside of 400.0% from the stock's current price. View Analyst Price Targets for Xeris Pharmaceuticals.

What is the consensus analysts' recommendation for Xeris Pharmaceuticals?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Xeris Pharmaceuticals in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Xeris Pharmaceuticals.

What are Wall Street analysts saying about Xeris Pharmaceuticals stock?

Here are some recent quotes from research analysts about Xeris Pharmaceuticals stock:
  • 1. According to Zacks Investment Research, "Xeris Pharmaceuticals, Inc. produces peptides, proteins, antibodies, molecules, auto-injectors, multi-dose pens and infusion pumps to treat endocrine and metabolic diseases. The company's proprietary formulation technologies consist of XeriSol (TM) and XeriJect(TM). Xeris Pharmaceuticals, Inc. is based in Chicago, United States. " (2/14/2020)
  • 2. Mizuho analysts commented, "We applied a weighted average valuation methodology (DCF+EV/Sales) to derive our $27 PT. Our assumptions include: Launch of the glucagon rescue pen in the U.S. market in 4Q19, with unadjusted peak-sales of $454 mil in 2028 (current PoS: 90%)." (9/10/2019)

Has Xeris Pharmaceuticals been receiving favorable news coverage?

News coverage about XERS stock has been trending somewhat positive recently, according to InfoTrie Sentiment Analysis. The research group identifies negative and positive press coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Xeris Pharmaceuticals earned a media sentiment score of 2.0 on InfoTrie's scale. They also gave news coverage about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the company's share price in the near future. View News Stories for Xeris Pharmaceuticals.

What other stocks do shareholders of Xeris Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Xeris Pharmaceuticals investors own include Amicus Therapeutics (FOLD), Zynerba Pharmaceuticals (ZYNE), AbbVie (ABBV), Agile Therapeutics (AGRX), Amarin (AMRN), Kala Pharmaceuticals (KALA), Omeros (OMER), Strongbridge Biopharma (SBBP), TG Therapeutics (TGTX) and InVitae (NVTA).

Who are Xeris Pharmaceuticals' key executives?

Xeris Pharmaceuticals' management team includes the folowing people:
  • Mr. Paul R. Edick, Pres, CEO & Chairman (Age 63)
  • Mr. Barry M. Deutsch, Chief Financial Officer (Age 54)
  • Mr. John P. Shannon, Exec. VP & COO (Age 57)
  • Dr. Steven J. Prestrelski, Co-Founder & Chief Scientific Officer (Age 55)
  • Ms. Allison Wey, Sr. VP of Investor Relations & Corp. Communications

When did Xeris Pharmaceuticals IPO?

(XERS) raised $75 million in an initial public offering on Thursday, June 21st 2018. The company issued 5,000,000 shares at $14.00-$16.00 per share. Jefferies, Leerink Partners and RBC Capital Markets acted as the underwriters for the IPO and Mizuho Securities was co-manager.

Who are Xeris Pharmaceuticals' major shareholders?

Xeris Pharmaceuticals' stock is owned by a variety of of retail and institutional investors. Top institutional investors include Citigroup Inc. (8.15%), ArrowMark Colorado Holdings LLC (7.14%), State Street Corp (1.85%), Blackstone Group Inc (1.67%), Bank of New York Mellon Corp (0.31%) and UBS Group AG (0.16%). Company insiders that own Xeris Pharmaceuticals stock include Beth Hecht, James E Flynn, Palmetto Partners, Ltd, Paul R Edick, Redmile Group, Llc and Steven Prestrelski. View Institutional Ownership Trends for Xeris Pharmaceuticals.

Which major investors are selling Xeris Pharmaceuticals stock?

XERS stock was sold by a variety of institutional investors in the last quarter, including New York State Common Retirement Fund, Goldman Sachs Group Inc. and Bank of America Corp DE. View Insider Buying and Selling for Xeris Pharmaceuticals.

Which major investors are buying Xeris Pharmaceuticals stock?

XERS stock was purchased by a variety of institutional investors in the last quarter, including Citigroup Inc., Blackstone Group Inc, ArrowMark Colorado Holdings LLC, California Public Employees Retirement System, State Street Corp, Marshall Wace LLP, Marshall Wace North America L.P. and UBS Group AG. Company insiders that have bought Xeris Pharmaceuticals stock in the last two years include Beth Hecht, James E Flynn, Palmetto Partners, Ltd, Paul R Edick and Redmile Group, Llc. View Insider Buying and Selling for Xeris Pharmaceuticals.

How do I buy shares of Xeris Pharmaceuticals?

Shares of XERS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Xeris Pharmaceuticals' stock price today?

One share of XERS stock can currently be purchased for approximately $4.00.


MarketBeat Community Rating for Xeris Pharmaceuticals (NASDAQ XERS)

Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  86 (Vote Outperform)
Underperform Votes:  97 (Vote Underperform)
Total Votes:  183
MarketBeat's community ratings are surveys of what our community members think about Xeris Pharmaceuticals and other stocks. Vote "Outperform" if you believe XERS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe XERS will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/17/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel